PROMIS 测量可用于评估长期造血细胞移植幸存者的症状和功能。
PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors.
机构信息
Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
出版信息
Cancer. 2018 Feb 15;124(4):841-849. doi: 10.1002/cncr.31089. Epub 2017 Oct 26.
BACKGROUND
Patient-reported outcomes for hematopoietic cell transplantation (HCT) survivors are well characterized with established measures; however, there is little experience with the new, freely available Patient-Reported Outcomes Measurement Information System (PROMIS) measures in this population. The aim of this study was to compare the performance of the PROMIS measures in the HCT setting with the performance of the commonly used 36-Item Short Form Health Survey (SF-36).
METHODS
Adult HCT survivors from the Fred Hutchinson Cancer Research Center (n = 4446) were mailed a survey that included the following as part of an annual follow-up survey: the Patient-Reported Outcomes Measurement Information System-Global Health (PROMIS-GH; 10 questions), the 29-Item Patient-Reported Outcomes Measurement Information System Profile (PROMIS-29), and the SF-36.
RESULTS
Both the SF-36 and PROMIS measures were available for 1634 HCT recipients (503 autologous recipients and 1131 allogeneic recipients). The overall response rate was 46%. The median time after transplantation for allogeneic and autologous recipients was 12.0 years (range, 0.4-44.1 years) and 6.1 years (range, 0.4-30.1 years), respectively. With the SF-36 or PROMIS-GH, overall physical functioning was somewhat lower in comparison with the general population, but mental functioning was similar. Component and domain scores with similar contents were strongly correlated by Pearson correlation coefficients: the Global Health-Physical and SF-36 Physical Component Summary scores for autologous (r = 0.82) and allogeneic recipients (r = 0.83) and the PROMIS-29 and SF-36 physical function, pain, and vitality/fatigue scores for allogeneic (0.87, -0.82, and -0.82, respectively) and autologous recipients (0.84, -0.82, and -0.81, respectively). The correlation between the Global Health-Mental and SF-36 Mental Component Summary scores was lower (0.70 for autologous recipients and 0.72 for allogeneic recipients).
CONCLUSIONS
Physical and mental symptoms and function in autologous and allogeneic HCT survivors can be adequately assessed with PROMIS-29 and PROMIS-GH. Cancer 2018;124:841-9. © 2017 American Cancer Society.
背景
造血细胞移植（HCT）幸存者的患者报告结局已经通过既定的评估方法得到了很好的描述；然而，在该人群中使用新的、免费的患者报告结局测量信息系统（PROMIS）评估方法的经验却很少。本研究的目的是比较 PROMIS 评估方法在 HCT 环境中的表现与常用的 36 项简短健康调查问卷（SF-36）的表现。
方法
弗雷德哈钦森癌症研究中心（Fred Hutchinson Cancer Research Center）的成年 HCT 幸存者（n = 4446）收到了一份调查问卷，该问卷作为年度随访调查的一部分，包括以下内容：患者报告结局测量信息系统-全球健康（PROMIS-GH；10 个问题）、29 项患者报告结局测量信息系统简表（PROMIS-29）和 SF-36。
结果
1634 例 HCT 受者（503 例自体受者和 1131 例异基因受者）同时具有 SF-36 和 PROMIS 评估方法。总体回复率为 46%。异基因和自体受者接受移植后的中位时间分别为 12.0 年（范围：0.4-44.1 年）和 6.1 年（范围：0.4-30.1 年）。SF-36 或 PROMIS-GH 评估的整体生理功能与一般人群相比略低，但心理功能相似。具有相似内容的组成和域评分通过皮尔逊相关系数强烈相关：自体（r = 0.82）和异基因（r = 0.83）受者的全球健康-生理和 SF-36 生理成分总分，以及异基因（0.87、-0.82 和-0.82）和自体（0.84、-0.82 和-0.81）受者的 PROMIS-29 和 SF-36 生理功能、疼痛和活力/疲劳评分。全球健康-心理和 SF-36 心理成分总分之间的相关性较低（自体受者为 0.70，异基因受者为 0.72）。
结论
自体和异基因 HCT 幸存者的生理和心理症状及功能可以通过 PROMIS-29 和 PROMIS-GH 进行充分评估。癌症 2018；124：841-9。©2017 美国癌症协会。
Zotero 插件